Saida Dashdamirova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Saida Dashdamirova has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Can Ilgin
Radiation Oncology Department, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
3 shared publications - Ceyda Dincer Yazan
Marmara University School of Medicine, Department of Endocrinology and Metabolism 1
3 shared publications - Goncagul Haklar
Department of Biochemistry, School of Medicine, Marmara University, Istanbul, Turkey
3 shared publications - Hulya Gozu
Department of Endocrinology and Metabolism Marmara University School of Medicine Istanbul Turkey
3 shared publications - Onur Elbasan
Department of Endocrinology and Metabolism Marmara University School of Medicine Istanbul Turkey
3 shared publications - Tugce Apaydin
Department of Endocrinology and Metabolism, Marmara University School of Medicine, Istanbul, Turkey.
3 shared publications
Latest Publications
- Open Access
- 13 February 2026
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 37 (5) , 564-572
Prevalence of Latent and Active Tuberculosis Infection in Inflammatory Bowel Disease Patients Who Received Biological Treatment
Background/Aims: This study aims to assess the frequency of latent tuberculosis (TB) and the incidence of active TB infection in patients with inflammatory bowel disease (IBD) and Behçet’s syndrome with gastrointestinal involvement who received either tumor necrosis factor–alpha (TNF-α) antagonist therapy or vedolizumab as a second-line biologic treatment following TNF-α antagonist therapy. Materials and Methods: A total of 349 patients were included in the study. Demographic data, disease characteristics, TB screening results, prophylactic treatment regimens and the duration, as well as side effects were collected from patient records. Results: Among the patients, 196 (56.1%) were male, with a mean age of 42 years and a mean disease duration of 10 Å} 6 years. A total of 267 (76.5%) had Crohn’s disease, 76 (21.8%) had ulcerative colitis, 3 had indeterminate colitis (0.8%), and 3 had Behçet’s syndrome with gastrointestinal involvement (0.8%). Latent TB was diagnosed in 176 (50.4%) patients, and 162 (92%) of them received isoniazid prophylaxis. Six (1.7%) patients developed active TB infection during the treatment period, occurring between 2 and 48 months after initiating TNF-α antagonist therapy. No cases of tuberculosis were observed in patients who had vedolizumab treatment. Among those who developed TB, 3 patients had pulmonary TB, and 3 had both pulmonary and extrapulmonary TB. No significant association was found between TB development and IBD phenotype or isoniazid use. Conclusion: Despite latent TB screening and prophylactic treatment, patients receiving TNF-α antagonists remain at risk of developing active TB, with a latent TB prevalence of 50.4% and an active TB incidence of 1.7%. These findings underscore the continued need for vigilance and robust TB monitoring strategies in this patient population. Cite this article as: Dashdamirova S, Eskazan T, Erzin YZ, et al. Prevalence of latent and active tuberculosis infection in inflammatory bowel disease patients who received biological treatment. Turk J Gastroenterol.Published online February 13, 2026. doi: 10.5152/tjg.2026.25072.
- 13 February 2026
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 37 (5) , 564-572
Open AccessPrevalence of Latent and Active Tuberculosis Infection in Inflammatory Bowel Disease Patients Who Received Biological Treatment
Background/Aims: This study aims to assess the frequency of latent tuberculosis (TB) and the incidence of active TB infection in patients with inflammatory bowel disease (IBD) and Behçet’s syndrome with gastrointestinal involvement who received either tumor necrosis factor–alpha (TNF-α) antagonist therapy or vedolizumab as a second-line biologic treatment following TNF-α antagonist therapy. Materials and Methods: A total of 349 patients were included in the study. Demographic data, disease characteristics, TB screening results, prophylactic treatment regimens and the duration, as well as side effects were collected from patient records. Results: Among the patients, 196 (56.1%) were male, with a mean age of 42 years and a mean disease duration of 10 Å} 6 years. A total of 267 (76.5%) had Crohn’s disease, 76 (21.8%) had ulcerative colitis, 3 had indeterminate colitis (0.8%), and 3 had Behçet’s syndrome with gastrointestinal involvement (0.8%). Latent TB was diagnosed in 176 (50.4%) patients, and 162 (92%) of them received isoniazid prophylaxis. Six (1.7%) patients developed active TB infection during the treatment period, occurring between 2 and 48 months after initiating TNF-α antagonist therapy. No cases of tuberculosis were observed in patients who had vedolizumab treatment. Among those who developed TB, 3 patients had pulmonary TB, and 3 had both pulmonary and extrapulmonary TB. No significant association was found between TB development and IBD phenotype or isoniazid use. Conclusion: Despite latent TB screening and prophylactic treatment, patients receiving TNF-α antagonists remain at risk of developing active TB, with a latent TB prevalence of 50.4% and an active TB incidence of 1.7%. These findings underscore the continued need for vigilance and robust TB monitoring strategies in this patient population. Cite this article as: Dashdamirova S, Eskazan T, Erzin YZ, et al. Prevalence of latent and active tuberculosis infection in inflammatory bowel disease patients who received biological treatment. Turk J Gastroenterol.Published online February 13, 2026. doi: 10.5152/tjg.2026.25072.
- Open Access
The association of free testosterone levels with coronavirus disease 2019
Background: Angiotensin‐converting enzyme 2 and transmembrane protease serine 2 are critical factors of virus transmission. Expression of angiotensin‐converting enzyme 2 is highest in testes, and testicular function and testosterone levels were affected by coronavirus disease 2019. Low testosterone levels are related to infections, especially respiratory tract infections, and could worsen clinical conditions by exacerbating cytokine storms and increasing pro‐inflammatory cytokines.Objectives: We aimed to evaluate the acute and chronic effects of coronavirus disease 2019 on gonadal functions. Our second aim was to detect the relationship between free testosterone levels and disease prognosis and determine the impact of low‐free testosterone on admission to the intensive care unit.Methods: Eighty‐one patients with reverse‐transcription polymerase chain reaction‐confirmed coronavirus disease 2019 were enrolled. Twenty‐nine patients were assessed again for 6 months post‐coronavirus disease 2019 follow‐up, and seven of them had a semen analysis. Serum follicle‐stimulating hormone, luteinizing hormone, sex hormone‐binding globulin, and total testosterone levels were measured.Results: In this observational study, 71.6% (n = 58) of patients had low free testosterone levels at baseline, in which 69% were considered secondary hypogonadism. A longer length of hospitalization and increased inflammatory markers (d‐dimer, high‐sensitive C‐reactive protein, and procalcitonin) were detected in the low‐free testosterone group. Follicle‐stimulating hormone, total, free, and bioavailable testosterone levels were lower in patients who required admission to the intensive care unit. Free testosterone levels were inversely correlated with the length of hospitalization and prognostic disease factors. Oligozoospermia and impaired progressive motility were present in 42.8% (3/7) of the patients. In 6 months post‐coronavirus disease 2019 follow‐up, out of 29 patients, 48.2% still had low testosterone levels.Conclusion: A high rate of hypogonadism (71.6%) was found, especially secondary hypogonadism, and about half of the patients had hypogonadism in the sixth months' follow‐up. Low free testosterone levels were correlated with inflammatory parameters, and it is related to the intensive care unit admission. Studies with long‐term follow‐up data in larger groups are needed to determine persistent hypogonadism and impaired spermatogenesis.
Open AccessThe association of free testosterone levels with coronavirus disease 2019
Background: Angiotensin‐converting enzyme 2 and transmembrane protease serine 2 are critical factors of virus transmission. Expression of angiotensin‐converting enzyme 2 is highest in testes, and testicular function and testosterone levels were affected by coronavirus disease 2019. Low testosterone levels are related to infections, especially respiratory tract infections, and could worsen clinical conditions by exacerbating cytokine storms and increasing pro‐inflammatory cytokines.Objectives: We aimed to evaluate the acute and chronic effects of coronavirus disease 2019 on gonadal functions. Our second aim was to detect the relationship between free testosterone levels and disease prognosis and determine the impact of low‐free testosterone on admission to the intensive care unit.Methods: Eighty‐one patients with reverse‐transcription polymerase chain reaction‐confirmed coronavirus disease 2019 were enrolled. Twenty‐nine patients were assessed again for 6 months post‐coronavirus disease 2019 follow‐up, and seven of them had a semen analysis. Serum follicle‐stimulating hormone, luteinizing hormone, sex hormone‐binding globulin, and total testosterone levels were measured.Results: In this observational study, 71.6% (n = 58) of patients had low free testosterone levels at baseline, in which 69% were considered secondary hypogonadism. A longer length of hospitalization and increased inflammatory markers (d‐dimer, high‐sensitive C‐reactive protein, and procalcitonin) were detected in the low‐free testosterone group. Follicle‐stimulating hormone, total, free, and bioavailable testosterone levels were lower in patients who required admission to the intensive care unit. Free testosterone levels were inversely correlated with the length of hospitalization and prognostic disease factors. Oligozoospermia and impaired progressive motility were present in 42.8% (3/7) of the patients. In 6 months post‐coronavirus disease 2019 follow‐up, out of 29 patients, 48.2% still had low testosterone levels.Conclusion: A high rate of hypogonadism (71.6%) was found, especially secondary hypogonadism, and about half of the patients had hypogonadism in the sixth months' follow‐up. Low free testosterone levels were correlated with inflammatory parameters, and it is related to the intensive care unit admission. Studies with long‐term follow‐up data in larger groups are needed to determine persistent hypogonadism and impaired spermatogenesis.
- Open Access
- 17 December 2021
- Published by Wiley in Clinical Endocrinology
- Vol. 96 (6) , 819-830
Effects of vitamin D receptor gene polymorphisms on the prognosis of COVID‐19
Purpose: Vitamin D deficiency has emerged as another potential risk factor for coronavirus disease (COVID‐19) due to the immunomodulatory effects of 25 hydroxyvitamin D [25 (OH)D]. Vitamin D receptor (VDR) gene polymorphisms such as Fok I, Bsm I, Apa I, and Taq I are also associated with different courses of viral infections. This study aimed to evaluate the association between the VDR gene polymorphism at Fok I, Taq I, Bsm I, and Apa I genotypes and the prognosis of COVID‐19 in respect to vitamin D deficiency.Methods: Two‐hundred ninety‐seven patients with COVID‐19 were enrolled. Serum 25 (OH)D levels were measured. Four variant regions of the VDR gene, FokI, BsmI, ApaI, and TaqI were determined.Results: Eighty‐three percent of subjects had vitamin D deficiency, and 40.7% of the whole group had severe deficiency. Median 25 (OH)D level was 11.97 ng/ml. Vitamin D levels were not related to inflammatory markers, disease severity, admission to intensive care unit (ICU), and mortality. While disease severity was related to Fok I Ff genotype, it was Taq TT genotype for ICU admission. Moreover, the ApaI aa genotype was common among the patients who were died. None of the deceased subjects had the Fok I FF genotype.Conclusion: 25 (OH)D levels were not related to the severity and mortality of COVID‐19. VDR gene polymorphisms are independently associated with the severity of COVID‐19 and the survival of patients.
- 17 December 2021
- Published by Wiley in Clinical Endocrinology
- Vol. 96 (6) , 819-830
Open AccessEffects of vitamin D receptor gene polymorphisms on the prognosis of COVID‐19
Purpose: Vitamin D deficiency has emerged as another potential risk factor for coronavirus disease (COVID‐19) due to the immunomodulatory effects of 25 hydroxyvitamin D [25 (OH)D]. Vitamin D receptor (VDR) gene polymorphisms such as Fok I, Bsm I, Apa I, and Taq I are also associated with different courses of viral infections. This study aimed to evaluate the association between the VDR gene polymorphism at Fok I, Taq I, Bsm I, and Apa I genotypes and the prognosis of COVID‐19 in respect to vitamin D deficiency.Methods: Two‐hundred ninety‐seven patients with COVID‐19 were enrolled. Serum 25 (OH)D levels were measured. Four variant regions of the VDR gene, FokI, BsmI, ApaI, and TaqI were determined.Results: Eighty‐three percent of subjects had vitamin D deficiency, and 40.7% of the whole group had severe deficiency. Median 25 (OH)D level was 11.97 ng/ml. Vitamin D levels were not related to inflammatory markers, disease severity, admission to intensive care unit (ICU), and mortality. While disease severity was related to Fok I Ff genotype, it was Taq TT genotype for ICU admission. Moreover, the ApaI aa genotype was common among the patients who were died. None of the deceased subjects had the Fok I FF genotype.Conclusion: 25 (OH)D levels were not related to the severity and mortality of COVID‐19. VDR gene polymorphisms are independently associated with the severity of COVID‐19 and the survival of patients.
- Open Access
- 13 August 2021
- Published by Hindawi Limited in International Journal of Endocrinology
- Vol. 2021, 1-11
The Association of Thyroid Hormone Changes with Inflammatory Status and Prognosis in COVID-19
Background. COVID-19 infection may have multiorgan effects in addition to effects on the lungs and immune system. Recently, studies have found thyroid function abnormalities in COVID-19 cases which were interpreted as euthyroid sick syndrome (ESS) or destructive thyroiditis. Therefore, in this study, we aimed to evaluate the thyroid function status and thyroid autoimmunity in COVID-19 patients. Material and Method. 205 patients were included. The medical history and laboratory parameters at admission were collected from medical records. Serum thyroid-stimulating hormone (TSH), free thyroxine (FT4), free triiodothyronine (FT3), thyroid peroxidase antibody, and thyroglobulin antibody were measured, and patients were classified according to thyroid function status. Results. 34.1% of the patients were euthyroid. Length of hospitalization ( ), rate of oxygen demand ( ), and intensive care unit (ICU) admission ( ) were lower, and none of the euthyroid patients died. 108 (52.6%) patients were classified to have ESS, 57 were classified as mild, and 51 were moderate. The inflammatory parameters were higher in patients with moderate ESS. In cluster analysis, a high-risk group with a lower median FT3 value (median = 2.34 ng/L; IQR = 0.86), a higher median FT4 value (median = 1.04 ng/dL; IQR = 0.33), and a lower median TSH value (median = 0.62 mIU/L; IQR = 0.59) included 8 of 9 died patients and 25 of the 31 patients that were admitted to ICU. Discussion. Length of hospitalization, oxygen demand, ICU admission, and mortality were lower in euthyroid patients. Moreover, none of the euthyroid patients died. In conclusion, evaluation of thyroid function tests during COVID-19 infection may give information about the prognosis of disease.
- 13 August 2021
- Published by Hindawi Limited in International Journal of Endocrinology
- Vol. 2021, 1-11
Open AccessThe Association of Thyroid Hormone Changes with Inflammatory Status and Prognosis in COVID-19
Background. COVID-19 infection may have multiorgan effects in addition to effects on the lungs and immune system. Recently, studies have found thyroid function abnormalities in COVID-19 cases which were interpreted as euthyroid sick syndrome (ESS) or destructive thyroiditis. Therefore, in this study, we aimed to evaluate the thyroid function status and thyroid autoimmunity in COVID-19 patients. Material and Method. 205 patients were included. The medical history and laboratory parameters at admission were collected from medical records. Serum thyroid-stimulating hormone (TSH), free thyroxine (FT4), free triiodothyronine (FT3), thyroid peroxidase antibody, and thyroglobulin antibody were measured, and patients were classified according to thyroid function status. Results. 34.1% of the patients were euthyroid. Length of hospitalization ( ), rate of oxygen demand ( ), and intensive care unit (ICU) admission ( ) were lower, and none of the euthyroid patients died. 108 (52.6%) patients were classified to have ESS, 57 were classified as mild, and 51 were moderate. The inflammatory parameters were higher in patients with moderate ESS. In cluster analysis, a high-risk group with a lower median FT3 value (median = 2.34 ng/L; IQR = 0.86), a higher median FT4 value (median = 1.04 ng/dL; IQR = 0.33), and a lower median TSH value (median = 0.62 mIU/L; IQR = 0.59) included 8 of 9 died patients and 25 of the 31 patients that were admitted to ICU. Discussion. Length of hospitalization, oxygen demand, ICU admission, and mortality were lower in euthyroid patients. Moreover, none of the euthyroid patients died. In conclusion, evaluation of thyroid function tests during COVID-19 infection may give information about the prognosis of disease.